Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $86.24 million. The enterprise value is $76.17 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 239.57 million shares outstanding. The number of shares has increased by 26.28% in one year.
| Current Share Class | 239.57M |
| Shares Outstanding | 239.57M |
| Shares Change (YoY) | +26.28% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 1.00% |
| Float | 237.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| Forward PS | 4.27 |
| PB Ratio | 3.07 |
| P/TBV Ratio | 4.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.69, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.69 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -106.52% and return on invested capital (ROIC) is -44.49%.
| Return on Equity (ROE) | -106.52% |
| Return on Assets (ROA) | -16.25% |
| Return on Invested Capital (ROIC) | -44.49% |
| Return on Capital Employed (ROCE) | -123.06% |
| Revenue Per Employee | $1.41M |
| Profits Per Employee | -$482,886 |
| Employee Count | 105 |
| Asset Turnover | 0.79 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $308,000 in taxes.
| Income Tax | 308,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.19% in the last 52 weeks. The beta is 0.89, so Vaxart's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -41.19% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 46.98 |
| Average Volume (20 Days) | 630,256 |
Short Selling Information
The latest short interest is 21.17 million, so 8.84% of the outstanding shares have been sold short.
| Short Interest | 21.17M |
| Short Previous Month | 14.68M |
| Short % of Shares Out | 8.84% |
| Short % of Float | 8.92% |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, Vaxart had revenue of $148.20 million and -$50.70 million in losses. Loss per share was -$0.22.
| Revenue | 148.20M |
| Gross Profit | -30.88M |
| Operating Income | -48.84M |
| Pretax Income | -50.40M |
| Net Income | -50.70M |
| EBITDA | -40.08M |
| EBIT | -48.84M |
| Loss Per Share | -$0.22 |
Full Income StatementBalance Sheet
The company has $28.79 million in cash and $18.96 million in debt, giving a net cash position of $9.84 million or $0.04 per share.
| Cash & Cash Equivalents | 28.79M |
| Total Debt | 18.96M |
| Net Cash | 9.84M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | 26.76M |
| Book Value Per Share | 0.12 |
| Working Capital | -51.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.29 million and capital expenditures -$188,000, giving a free cash flow of -$30.48 million.
| Operating Cash Flow | -30.29M |
| Capital Expenditures | -188,000 |
| Free Cash Flow | -30.48M |
| FCF Per Share | -$0.13 |
Full Cash Flow StatementMargins
Gross margin is -20.83%, with operating and profit margins of -32.96% and -34.21%.
| Gross Margin | -20.83% |
| Operating Margin | -32.96% |
| Pretax Margin | -34.00% |
| Profit Margin | -34.21% |
| EBITDA Margin | -27.04% |
| EBIT Margin | -32.96% |
| FCF Margin | n/a |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.28% |
| Shareholder Yield | -26.28% |
| Earnings Yield | -58.95% |
| FCF Yield | -35.44% |
Dividend DetailsAnalyst Forecast
The average price target for Vaxart is $2.00, which is 455.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.00 |
| Price Target Difference | 455.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 29.19% |
| EPS Growth Forecast (5Y) | 0.02% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -3.41 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.41 |
| Piotroski F-Score | 4 |
